<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642365</url>
  </required_header>
  <id_info>
    <org_study_id>BP42595</org_study_id>
    <secondary_id>2020-003164-82</secondary_id>
    <nct_id>NCT04642365</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.</brief_title>
  <official_title>An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and preliminary anti-tumor activity of&#xD;
      RO7296682 in combination with Atezolizumab in participants with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 31 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 31 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) (Part II and III only)</measure>
    <time_frame>Up to 31 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (Part I only)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Curve (AUC) of RO7296682</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Concentration (Cmin) of RO7296682</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of RO7296682</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax) of RO7296682</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady-state conditions (Vss) of RO7296682</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t~1/2) of RO7296682</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-induced changes in Treg levels in blood and/or tumor as compared to baseline</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-induced changes in Treg/Teff (T-regulatory cell; T-effector cell) ratio in blood and/or tumor as compared to baseline</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682 with a fixed dose of Atezolizumab, every three weeks (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I. Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III (Exploratory)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I and if clinical activity is seen in this trial or in the single agent study (WP41188). Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab at the dosing regimen established in Part I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7296682</intervention_name>
    <description>RO7296682 will be administered as per the schedules specified in the respective arms.</description>
    <arm_group_label>Part I</arm_group_label>
    <arm_group_label>Part II</arm_group_label>
    <arm_group_label>Part III (Exploratory)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered as per the schedules specified in the respective arms.</description>
    <arm_group_label>Part I</arm_group_label>
    <arm_group_label>Part II</arm_group_label>
    <arm_group_label>Part III (Exploratory)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Diagnosis of advanced and/or metastatic solid tumors who have progressed on a standard&#xD;
        therapy, are intolerant to standard of care (SoC), and/or and non-amenable to SoC.&#xD;
&#xD;
        Participants whose tumors have known sensitizing mutations must have experienced disease&#xD;
        progression (during or after treatment) or intolerance to treatment with a respective&#xD;
        targeted therapy.&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          -  Able to provide the most recent archival tumor tissue samples.&#xD;
&#xD;
          -  Adequate cardiovascular, haematological, liver and renal function.&#xD;
&#xD;
          -  Participants on therapeutic anticoagulation must be on a stable anticoagulant regimen.&#xD;
&#xD;
          -  Women of Childbearing Potential: Agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use highly effective contraceptive methods.&#xD;
&#xD;
          -  Men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             highly effective contraceptive methods and refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation, or breastfeeding.&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of RO7296682 and atezolizumab,&#xD;
             including but not limited to hypersensitivity to Chinese hamster ovary cell products&#xD;
             or other recombinant human or humanized antibodies.&#xD;
&#xD;
          -  History or clinical evidence of central nervous system (CNS) primary tumors or&#xD;
             metastases.&#xD;
&#xD;
          -  Participants with another invasive malignancy in the last two years.&#xD;
&#xD;
          -  Participants with known active or uncontrolled infection.&#xD;
&#xD;
          -  Positive HIV test at screening.&#xD;
&#xD;
          -  Positive for Hepatitis B and C.&#xD;
&#xD;
          -  Vaccination with live vaccines within 28 days prior to C1D1.&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury within 28 days prior to first&#xD;
             RO7296682 and atezolizumab infusion.&#xD;
&#xD;
          -  Participants with wound healing complications.&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit informed consent.&#xD;
&#xD;
          -  History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS (drug rash&#xD;
             with eosinophilia and systemic symptoms).&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency.&#xD;
&#xD;
          -  Prior treatment with CPIs (e.g. anti-CTLA4, anti-PD1, anti-PDL1), immunomodulatory&#xD;
             monoclonal antibodies (mAbs) and/or mAb-derived therapies (approved or&#xD;
             investigational) is approved.&#xD;
&#xD;
          -  Treatment with standard radiotherapy, any chemotherapeutic agent, targeted therapy or&#xD;
             treatment with any other investigational drug (defined as treatment for which there is&#xD;
             currently no regulatory authority-approved indication) within 28 days or 5 half-lives&#xD;
             of the drug (whichever is shorter), prior to the first RO7296882 administration on&#xD;
             C1D1.&#xD;
&#xD;
          -  Radiotherapy within the last 4 weeks before start of study drug treatment, with the&#xD;
             exception of limited palliative radiotherapy (for which no wash out period is&#xD;
             required).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP42595 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Maccallum Cancer Institute; Clinical Trial Unit</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2H 6C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Onkologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RG6292</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

